Image de Google Jackets
Vue normale Vue MARC vue ISBD

New 2023 classification criteria for antiphospholipid syndrome (ACR/EULAR 2023)

Par : Contributeur(s) : Type de matériel : TexteTexteLangue : français Détails de publication : 2023. Ressources en ligne : Abrégé : Antiphospholipid syndrome (APS) is a rare autoimmune disease characterized by thromboses and obstetrical morbidity, linked to the presence of antibodies directed against cell membranes. The Sapporo-Sydney classification criteria, in use since 1999 and updated in 2006, had limitations as they did not account for certain symptoms and lacked the ability to stratify based on the biological profile and cardiovascular risk factors. In 2015, an international effort led by the American College of Rheumatology (ACR) and the European Alliance of Associations For Rheumatology (EULAR) aimed to develop new classification criteria for APS. Published in August 2023, these criteria are highly specific and are hierarchically structured, weighted, and stratified based on the patient’s cardiovascular risk and biological profile. They reflect the current state of knowledge about APS, facilitating homogeneous inclusion of patients in scientific studies. These new criteria involve four steps for classifying a patient, including mandatory entry criteria and an assessment of clinical and biological manifestations. They are intended exclusively for research use, with considerations such as the exclusion of rare manifestations and non-specific low antibodies thresholds that may lead to debatable management. In the absence of classification according to the new criteria, the clinician’s judgment remains essential for therapeutic decisions based on current French and international guidelines.
Tags de cette bibliothèque : Pas de tags pour ce titre. Connectez-vous pour ajouter des tags.
Evaluations
    Classement moyen : 0.0 (0 votes)
Nous n'avons pas d'exemplaire de ce document

73

Antiphospholipid syndrome (APS) is a rare autoimmune disease characterized by thromboses and obstetrical morbidity, linked to the presence of antibodies directed against cell membranes. The Sapporo-Sydney classification criteria, in use since 1999 and updated in 2006, had limitations as they did not account for certain symptoms and lacked the ability to stratify based on the biological profile and cardiovascular risk factors. In 2015, an international effort led by the American College of Rheumatology (ACR) and the European Alliance of Associations For Rheumatology (EULAR) aimed to develop new classification criteria for APS. Published in August 2023, these criteria are highly specific and are hierarchically structured, weighted, and stratified based on the patient’s cardiovascular risk and biological profile. They reflect the current state of knowledge about APS, facilitating homogeneous inclusion of patients in scientific studies. These new criteria involve four steps for classifying a patient, including mandatory entry criteria and an assessment of clinical and biological manifestations. They are intended exclusively for research use, with considerations such as the exclusion of rare manifestations and non-specific low antibodies thresholds that may lead to debatable management. In the absence of classification according to the new criteria, the clinician’s judgment remains essential for therapeutic decisions based on current French and international guidelines.

PLUDOC

PLUDOC est la plateforme unique et centralisée de gestion des bibliothèques physiques et numériques de Guinée administré par le CEDUST. Elle est la plus grande base de données de ressources documentaires pour les Étudiants, Enseignants chercheurs et Chercheurs de Guinée.

Adresse

627 919 101/664 919 101

25 boulevard du commerce
Kaloum, Conakry, Guinée

Réseaux sociaux

Powered by Netsen Group @ 2025